An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 344 participants.
Also called NCT07234032
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 344 participants
- Sponsor
- Registry
-
NCT07234032
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Czechia, France, Georgia, Germany, Japan, South Korea, Spain
- Registry status
- Recruiting
Technical summary
Registry record NCT07234032. Allocation not applicable; no masking; primary purpose treatment. Start 2026-07-20 (actual); primary completion 2031-01-22 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Condition
- Pulmonary Hypertension
- Condition
- Interstitial Lung Disease
- Intervention (Drug)
- Treprostinil Palmitil Inhalation Powder
- Intervention (Drug)
- Placebo
- Lead sponsor
- Insmed Incorporated
Record details
- Record id
cardio:ct-nct07234032- Content hash
589fba4f0cf6a75448f6249e95a2a0b124b545dcbab7b8dcb2c4725f2e4f3cd6